{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:46:34Z","timestamp":1791942394055,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","award":["OTH-2018-12268"],"award-info":[{"award-number":["OTH-2018-12268"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease (FD) is a rare X-linked disease caused by mutations in GLA gene with consequent lysosomal accumulation of globotriaosylceramide (Gb3). Women with FD often show highly heterogeneous symptoms that can manifest from mild to severe phenotype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>The phenotypic variability of the clinical manifestations in heterozygous women with FD mainly depends on the degree and direction of inactivation of the X chromosome. Classical approaches to measure XCI skewness might be not sufficient to explain disease manifestation in women. In addition to unbalanced XCI, allele-specific DNA methylation at promoter of GLA gene may influence the expression levels of the mutated allele, thus impacting the onset and the outcome of FD. In this regard, analyses of DNA methylation at GLA promoter, performed by approaches allowing distinction between mutated and non-mutated allele, may be much more informative. The aim of this review is to critically evaluate recent literature articles addressing the potential role of DNA methylation in the context of FD. Although up to date relatively few works have addressed this point, reviewing all pertinent studies may help to evaluate the importance of DNA methylation analysis in FD and to develop new research and technologies aimed to predict whether the carrier females will develop symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Relatively few studies have addressed the complexity of DNA methylation landscape in FD that remains poorly investigated. The hope for the future is that ad hoc and ultradeep methylation analyses of GLA gene will provide epigenetic signatures able to predict whether pre-symptomatic female carriers will develop symptoms thus helping timely interventions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-021-01019-3","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T13:02:56Z","timestamp":1612270976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["DNA methylation impact on Fabry disease"],"prefix":"10.1186","volume":"13","author":[{"given":"Teodolinda","family":"Di Risi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Della Monica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirio","family":"Cocozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imbriaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6097-4171","authenticated-orcid":false,"given":"Lorenzo","family":"Chiariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000060184","volume":"136","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Wasserstein MP, Banikazemi M. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy. Contrib Nephrol. 2001;136:174\u201392.","journal-title":"Contrib Nephrol"},{"key":"1019_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/B978-0-444-62702-5.00017-2","volume":"132","author":"R Schiffmann","year":"2015","unstructured":"Schiffmann R. Fabry disease. Handb Clin Neurol. 2015;132:231\u201348.","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"1019_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"1","key":"1019_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31\u201340.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"1019_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/jhg.2013.48","volume":"58","author":"T Inoue","year":"2013","unstructured":"Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet. 2013;58(8):548\u201352.","journal-title":"J Hum Genet"},{"issue":"1","key":"1019_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1\u20139.","journal-title":"J Med Genet"},{"issue":"12","key":"1019_CR8","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.3390\/ijms19123726","volume":"19","author":"G Duro","year":"2018","unstructured":"Duro G, Zizzo C, Cammarata G, Burlina A, Burlina A, Polo G, et al. Mutations in the GLA gene and LysoGb3: is it really anderson-fabry disease? Int J Mol Sci. 2018;19(12):3726.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1019_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"21","key":"1019_CR10","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"issue":"1","key":"1019_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75(1):65\u201374.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"1019_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ymgme.2012.08.003","volume":"107","author":"A Pisani","year":"2012","unstructured":"Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, et al. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Mol Genet Metab. 2012;107(3):267\u201375.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1019_CR13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","volume":"28","author":"E Riccio","year":"2020","unstructured":"Riccio E, Zanfardino M, Ferreri L, Santoro C, Cocozza S, Capuano I, et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Eur J Hum Genet. 2020;28:1662\u20138.","journal-title":"Eur J Hum Genet"},{"key":"1019_CR15","doi-asserted-by":"crossref","unstructured":"Redonnet-Vernhet I, Ploos-van-Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet. 1996;33(8):682\u20138.","DOI":"10.1136\/jmg.33.8.682"},{"issue":"8","key":"1019_CR16","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1136\/jmg.40.8.e103","volume":"40","author":"A Morrone","year":"2003","unstructured":"Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, et al. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet. 2003;40(8):e103.","journal-title":"J Med Genet"},{"issue":"8","key":"1019_CR17","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","volume":"83","author":"R Dobrovolny","year":"2005","unstructured":"Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl). 2005;83(8):647\u201354.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"1019_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44\u201354.","journal-title":"Clin Genet"},{"issue":"451","key":"1019_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08035320600618809","volume":"95","author":"EM Maier","year":"2006","unstructured":"Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl. 2006;95(451):30\u20138.","journal-title":"Acta Paediatr Suppl"},{"issue":"2","key":"1019_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","volume":"505","author":"D Elstein","year":"2012","unstructured":"Elstein D, Schachamorov E, Beeri R, Altarescu G. X-inactivation in Fabry disease. Gene. 2012;505(2):266\u20138. https:\/\/doi.org\/10.1016\/j.gene.2012.06.013.","journal-title":"Gene"},{"key":"1019_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.gene.2017.10.064","volume":"641","author":"P Juchniewicz","year":"2018","unstructured":"Juchniewicz P, Kloska A, Tylki-Szyma\u0144ska A, Jak\u00f3bkiewicz-Banecka J, W\u0119grzyn G, Moskot M, et al. Female Fabry disease patients and X-chromosome inactivation. Gene. 2018;641:259\u201364.","journal-title":"Gene"},{"issue":"6","key":"1019_CR22","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1093\/hmg\/ddu564","volume":"24","author":"AM Cotton","year":"2015","unstructured":"Cotton AM, Price EM, Jones MJ, Balaton BP, Kobor MS, Brown CJ. Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation. Hum Mol Genet. 2015;24(6):1528\u201339.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"1019_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/jmedgenet-2019-106467","volume":"57","author":"DP Germain","year":"2020","unstructured":"Germain DP, Oliveira JP, Bichet DG, Yoo HW, Hopkin RJ, Lemay R, et al. Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLAvariants: a consensus classification system by a multispecialty Fabry disease genotype-phenotype workgroup. J Med Genet. 2020;57(8):542\u201351.","journal-title":"J Med Genet"},{"issue":"3","key":"1019_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40620-019-00663-6","volume":"33","author":"I Capuano","year":"2020","unstructured":"Capuano I, Garofalo C, Buonanno P, Pinelli M, Di Risi T, Feriozzi S, et al. Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995\u20132019. J Nephrol. 2020;33(3):569\u201381.","journal-title":"J Nephrol"},{"issue":"3","key":"1019_CR25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2214\/AJR.05.0442","volume":"188","author":"M Imbriaco","year":"2007","unstructured":"Imbriaco M, Spinelli L, Cuocolo A, Maurea S, Sica G, Quarantelli M, et al. MRI characterization of myocardial tissue in patients with Fabry\u2019s disease. AJR Am J Roentgenol. 2007;188(3):850\u20133.","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"1019_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/cge.12386","volume":"86","author":"A Pisani","year":"2014","unstructured":"Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, et al. The kidney in Fabry\u2019s disease. Clin Genet. 2014;86(4):301\u20139.","journal-title":"Clin Genet"},{"issue":"11","key":"1019_CR27","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1210\/jc.2006-0858","volume":"91","author":"A Faggiano","year":"2006","unstructured":"Faggiano A, Pisani A, Milone F, Gaccione M, Filippella M, Santoro A, et al. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab. 2006;91(11):4319\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1019_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","volume":"117","author":"G Messalli","year":"2012","unstructured":"Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L, et al. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med. 2012;117(1):19\u201328.","journal-title":"Radiol Med"},{"issue":"6","key":"1019_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1039\/C4MB00707G","volume":"11","author":"V Matafora","year":"2015","unstructured":"Matafora V, Cuccurullo M, Beneduci A, Petrazzuolo O, Simeone A, Anastasio P, et al. Early markers of Fabry disease revealed by proteomics. Mol Biosyst. 2015;11(6):1543\u201351.","journal-title":"Mol Biosyst"},{"issue":"10","key":"1019_CR30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","volume":"20","author":"MVC Greenberg","year":"2019","unstructured":"Greenberg MVC, Bourc\u2019his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20(10):590\u2013607.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"1019_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrg2341","volume":"9","author":"MM Suzuki","year":"2008","unstructured":"Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008;9(6):465\u201376.","journal-title":"Nat Rev Genet"},{"key":"1019_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fonc.2019.00489","volume":"9","author":"N Mahmood","year":"2019","unstructured":"Mahmood N, Rabbani SA. DNA methylation readers and cancer: mechanistic and therapeutic applications. Front Oncol. 2019;9:489.","journal-title":"Front Oncol"},{"issue":"8","key":"1019_CR33","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrg1655","volume":"6","author":"KD Robertson","year":"2005","unstructured":"Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6(8):597\u2013610.","journal-title":"Nat Rev Genet"},{"issue":"10","key":"1019_CR34","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1101\/gr.112680.110","volume":"21","author":"AJ Sharp","year":"2011","unstructured":"Sharp AJ, Stathaki E, Migliavacca E, Brahmachary M, Montgomery SB, Dupre Y, et al. DNA methylation profiles of human active and inactive X chromosomes. Genome Res. 2011;21(10):1592\u2013600.","journal-title":"Genome Res"},{"issue":"5","key":"1019_CR35","doi-asserted-by":"publisher","first-page":"a019133","DOI":"10.1101\/cshperspect.a019133","volume":"6","author":"E Li","year":"2014","unstructured":"Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol. 2014;6(5):a019133.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1019_CR36","doi-asserted-by":"crossref","unstructured":"Duncan CG, Grimm SA, Morgan DL, Bushel PR, Bennett BD, NISC Comparative Sequencing Program, et al. Dosage compensation and DNA methylation landscape of the X chromosome in mouse liver. Sci Rep. 2018;8(1):10138.","DOI":"10.1038\/s41598-018-28356-3"},{"key":"1019_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3389\/fcell.2019.00219","volume":"7","author":"H Fang","year":"2019","unstructured":"Fang H, Disteche CM, Berletch JB. X inactivation and escape: epigenetic and structural features. Front Cell Dev Biol. 2019;7:219.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"1019_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12041-015-0574-1","volume":"94","author":"CM Disteche","year":"2015","unstructured":"Disteche CM, Berletch JB. X-chromosome inactivation and escape. J Genet. 2015;94(4):591\u20139.","journal-title":"J Genet"},{"issue":"12","key":"1019_CR39","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/ejhg.2014.34","volume":"22","author":"JE Joo","year":"2014","unstructured":"Joo JE, Novakovic B, Cruickshank M, Doyle LW, Craig JM, Saffery R. Human active X-specific DNA methylation events showing stability across time and tissues. Eur J Hum Genet. 2014;22(12):1376\u201381.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1019_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s004390050909","volume":"104","author":"T Kubota","year":"1999","unstructured":"Kubota T, Nonoyama S, Tonoki H, Masuno M, Imaizumi K, Kojima M, et al. A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR. Hum Genet. 1999;104(1):49\u201355.","journal-title":"Hum Genet"},{"issue":"6","key":"1019_CR41","first-page":"1229","volume":"51","author":"RC Allen","year":"1992","unstructured":"Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51(6):1229\u201339.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"1019_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1042\/BST20170346","volume":"46","author":"A Keniry","year":"2018","unstructured":"Keniry A, Blewitt ME. Studying X chromosome inactivation in the single-cell genomic era. Biochem Soc Trans. 2018;46(3):577\u201386.","journal-title":"Biochem Soc Trans"},{"issue":"51","key":"1019_CR43","doi-asserted-by":"publisher","first-page":"13015","DOI":"10.1073\/pnas.1806811115","volume":"115","author":"M Garieri","year":"2018","unstructured":"Garieri M, Stamoulis G, Blanc X, Falconnet E, Ribaux P, Borel C, et al. Extensive cellular heterogeneity of X inactivation revealed by single-cell allele-specific expression in human fibroblasts. Proc Natl Acad Sci U S A. 2018;115(51):13015\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1019_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymgme.2017.01.002","volume":"120","author":"MA Hossain","year":"2017","unstructured":"Hossain MA, Yanagisawa H, Miyajima T, Wu C, Takamura A, Akiyama K, et al. The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome. Mol Genet Metab. 2017;120(3):173\u20139.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1019_CR45","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.ymgme.2019.03.003","volume":"126","author":"H Yanagisawa","year":"2019","unstructured":"Yanagisawa H, Hossain MA, Miyajima T, Nagao K, Miyashita T, Eto Y. Dysregulated DNA methylation of GLA gene was associated with dysfunction of autophagy. Mol Genet Metab. 2019;126(4):460\u20135.","journal-title":"Mol Genet Metab"},{"key":"1019_CR46","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.ymgmr.2019.100497","volume":"20","author":"MA Hossain","year":"2019","unstructured":"Hossain MA, Wu C, Yanagisawa H, Miyajima T, Akiyama K, Eto Y. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the GLAgene. Mol Genet Metab Rep. 2019;20:100497.","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"1019_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2174\/1381612820666141027113923","volume":"21","author":"H Ueda","year":"2015","unstructured":"Ueda H, Uchida H. Epigenetic modification in neuropathic pain. Curr Pharm Des. 2015;21(7):849\u201367.","journal-title":"Curr Pharm Des"},{"issue":"9647","key":"1019_CR48","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372(9647):1427\u201335.","journal-title":"Lancet"},{"issue":"33","key":"1019_CR49","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.2174\/13816128113199990387","volume":"19","author":"A Tuttolomondo","year":"2013","unstructured":"Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G, et al. Neurological complications of Anderson-Fabry disease. Curr Pharm Des. 2013;19(33):6014\u201330.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"1019_CR50","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ncpneuro0407","volume":"3","author":"AT M\u00f8ller","year":"2007","unstructured":"M\u00f8ller AT, Jensen TS. Neurological manifestations in Fabry\u2019s disease. Nat Clin Pract Neurol. 2007;3(2):95\u2013106.","journal-title":"Nat Clin Pract Neurol"},{"key":"1019_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgmr.2015.08.002","volume":"5","author":"A H\u00fcbner","year":"2015","unstructured":"H\u00fcbner A, Metz T, Schanzer A, Greber-Platzer S, Item CB. Aberrant DNA methylation of calcitonin receptor in Fabry patients treated with enzyme replacement therapy. Mol Genet Metab Rep. 2015;5:1\u20132.","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"1019_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/15592294.2016.1260211","volume":"12","author":"E Florio","year":"2017","unstructured":"Florio E, Keller S, Coretti L, Affinito O, Scala G, Errico F, et al. Tracking the evolution of epialleles during neural differentiation and brain development: D-Aspartate oxidase as a model gene. Epigenetics. 2017;12(1):41\u201354.","journal-title":"Epigenetics"},{"issue":"1","key":"1019_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13148-019-0732-z","volume":"11","author":"M Cuomo","year":"2019","unstructured":"Cuomo M, Keller S, Punzo D, Nuzzo T, Affinito O, Coretti L, et al. Selective demethylation of two CpG sites causes postnatal activation of the Dao gene and consequent removal of D-serine within the mouse cerebellum. Clin Epigenet. 2019;11(1):149.","journal-title":"Clin Epigenet"},{"issue":"1","key":"1019_CR54","doi-asserted-by":"publisher","first-page":"10163","DOI":"10.1038\/s41598-018-28332-x","volume":"8","author":"S Keller","year":"2018","unstructured":"Keller S, Punzo D, Cuomo M, Affinito O, Coretti L, Sacchi S, et al. DNA methylation landscape of the genes regulating D-serine and D-aspartate metabolism in post-mortem brain from controls and subjects with schizophrenia. Sci Rep. 2018;8(1):10163.","journal-title":"Sci Rep"},{"issue":"6","key":"1019_CR55","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/genes11060620","volume":"11","author":"G De Riso","year":"2020","unstructured":"De Riso G, Cuomo M, Di Risi T, Della Monica R, Buonaiuto M, Costabile D, et al. Ultra-deep DNA methylation analysis of X-linked genes: GLA and AR as model genes. Genes (Basel). 2020;11(6):620.","journal-title":"Genes (Basel)"},{"key":"1019_CR56","doi-asserted-by":"crossref","unstructured":"Rossanti R, Nozu K, Fukunaga A, Nagano C, Horinouchi T, Yamamura T, et al. X-chromosome inactivation patterns in females with Fabry disease examined by both utra-deep RNA sequencing and methylation-dependent assay. Research Square. 2020. Preprint.","DOI":"10.21203\/rs.3.rs-100840\/v1"},{"issue":"6409","key":"1019_CR57","doi-asserted-by":"publisher","first-page":"eaar3146","DOI":"10.1126\/science.aar3146","volume":"361","author":"V Onuchic","year":"2018","unstructured":"Onuchic V, Lurie E, Carrero I, Pawliczek P, Patel RY, Rozowsky J, et al. Allele-specific epigenome maps reveal sequence-dependent stochastic switching at regulatory loci. Science. 2018;361(6409):eaar3146.","journal-title":"Science"},{"issue":"4","key":"1019_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41587-020-0407-5","volume":"38","author":"T Gilpatrick","year":"2020","unstructured":"Gilpatrick T, Lee I, Graham JE, Raimondeau E, Bowen R, Heron A, Downs B, Sukumar S, Sedlazeck FJ, Timp W. Targeted nanopore sequencing with Cas9-guided adapter ligation. Nat Biotechnol. 2020;38(4):433\u20138.","journal-title":"Nat Biotechnol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13148-021-01019-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-021-01019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T02:04:55Z","timestamp":1612317895000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-021-01019-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1186\/s13148-021-01019-3","relation":{},"ISSN":["1868-7075","1868-7083"],"issn-type":[{"value":"1868-7075","type":"print"},{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}